Trial · NCT07887152
All-Oral Fluoroquinolone-Based Triple Therapies for Adults With Imaging-Confirmed Osteoarticular Brucellosis
NCT07887152, Not applicable, Not yet recruiting, The First Affiliated Hospital of Shihezi University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. All-Oral Fluoroquinolone-Based Triple Therapies for Adults With Imaging-Confirmed Osteoarticular Brucellosis. Trials, record NCT07887152. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07887152
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- All-Oral Fluoroquinolone-Based Triple Therapies for Adults With Imaging-Confirmed Osteoarticular Brucellosis
- NCT number
- NCT07887152
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 150 participants, estimated
- Lead sponsor
- The First Affiliated Hospital of Shihezi University
- Conditions
- Brucellosis, Osteoarticular Brucellosis
- Interventions
- Doxycycline + Rifampicin + Ceftriaxone (intravenous therapy for 4 weeks), Triple oral regimen (Doxycycline + Rifampicin + Levofloxacin), Triple oral regimen (Doxycycline + Rifampicin + Moxifloxacin)
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical cure rate at Week 12 (end of treatment) | 12 weeks after randomization (completion of 12-week treatment) | Composite clinical cure defined as resolution of systemic symptoms, ≥50 % reduction in visual analog scale (VAS) joint-pain score, and improvement of inflammatory markers at the end of 12-week treatment. Microbiological cure is reported as an exploratory supportive endpoint. |
| Secondary | Recurrence rate at 24 weeks post-treatment | 24 weeks after completion of 12-week therapy | Proportion of participants with confirmed osteoarticular brucellosis recurrence 24 weeks after treatment cessation. |
| Secondary | Recurrence rate at 48 weeks post-treatment | 48 weeks after completion of 12-week therapy | Proportion of participants with confirmed osteoarticular brucellosis recurrence 48 weeks after treatment cessation. |
| Secondary | Time to achieve ≥50 % reduction in VAS joint-pain score | Throughout the 12-week treatment period | 1\. Time (in weeks) from randomization until achieving at least 50 % reduction from baseline in VAS joint-pain score. |
| Secondary | Radiologic improvement rate at 24 and 48 weeks post-treatment | 24 weeks and 48 weeks after completion of 12-week therapy | Proportion of participants with radiologic improvement on CT or MRI imaging at 24-week and 48-week follow-up. |
| Secondary | Change in SF-36 health-related quality-of-life scores | Baseline, Week 12, Week 24, Week 48 | Change from baseline in 36-Item Short Form Health Survey (SF-36) quality-of-life scores measured at Week 12, Week 24, and Week 48. |
| Secondary | Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores | Baseline, Week 12, Week 24, Week 48 | Change from baseline in BASDAI functional scores assessed at Week 12, Week 24, and Week 48. |
| Secondary | Treatment completion rate (medication adherence >90 %) | 12-week treatment period | Proportion of participants with medication adherence greater than 90 % during the 12-week treatment course. |
| Secondary | Incidence of treatment-related adverse events | From treatment initiation through Week 48 | Treatment-related adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07887152
GET https://conductscience.org/api/trials/v1/NCT07887152/registered